I tend to agree with you on this. I think NWBO will be bought out immediately when we get an approval from U.K or FDA(this is a puzzle). Rember Merck has failed many trials recently and they need a therapy like DCVAX-L to expand their market. At the same time, they can start trials on DCVAX-D. If the results are as good as P I/II they do not need to complete the trial. They can wrap it up and apply for approval. They are big and have resources. NWBO could have continue with P I/II with getting more patients which will help them down the road. But they chose not to do that. My guess is the asking price will be north of $10 Bil.
This is my only post.
BTW- Do I like the above scenario. The answer is NO. But, NWBO lack of financials have put tremendous impact on company's progress.
Market Data 
Markets 
AI
